A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
Publication
, Journal Article
Bonomi, M; Bhateja, P; Issa, M; Klamer, B; Pan, X; Blakaj, A; Karivedu, V; Mousa, L; Mitchell, D; Gamez, M; Kang, S; Seim, NB; Old, M ...
Published in: Oral Oncol
November 2020
BACKGROUND: ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. PATIENTS AND METHODS: This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.
Duke Scholars
Published In
Oral Oncol
DOI
EISSN
1879-0593
Publication Date
November 2020
Volume
110
Start / End Page
104900
Location
England
Related Subject Headings
- Treatment Outcome
- Survival Rate
- Squamous Cell Carcinoma of Head and Neck
- Retrospective Studies
- Proportional Hazards Models
- Prognosis
- Oncology & Carcinogenesis
- Molecular Targeted Therapy
- Middle Aged
- Male
Citation
APA
Chicago
ICMJE
MLA
NLM
Bonomi, M., Bhateja, P., Issa, M., Klamer, B., Pan, X., Blakaj, A., … Blakaj, D. (2020). A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors. Oral Oncol, 110, 104900. https://doi.org/10.1016/j.oraloncology.2020.104900
Bonomi, M., P. Bhateja, M. Issa, B. Klamer, X. Pan, A. Blakaj, V. Karivedu, et al. “A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.” Oral Oncol 110 (November 2020): 104900. https://doi.org/10.1016/j.oraloncology.2020.104900.
Bonomi M, Bhateja P, Issa M, Klamer B, Pan X, Blakaj A, et al. A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors. Oral Oncol. 2020 Nov;110:104900.
Bonomi, M., et al. “A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.” Oral Oncol, vol. 110, Nov. 2020, p. 104900. Pubmed, doi:10.1016/j.oraloncology.2020.104900.
Bonomi M, Bhateja P, Issa M, Klamer B, Pan X, Blakaj A, Karivedu V, Mousa L, Mitchell D, Gamez M, Kang S, Seim NB, Old M, Carrau R, Rocco J, Blakaj D. A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors. Oral Oncol. 2020 Nov;110:104900.
Published In
Oral Oncol
DOI
EISSN
1879-0593
Publication Date
November 2020
Volume
110
Start / End Page
104900
Location
England
Related Subject Headings
- Treatment Outcome
- Survival Rate
- Squamous Cell Carcinoma of Head and Neck
- Retrospective Studies
- Proportional Hazards Models
- Prognosis
- Oncology & Carcinogenesis
- Molecular Targeted Therapy
- Middle Aged
- Male